Elamipretide (SS-31): the four-residue peptide that goes looking for cardiolipin

01.  What it actually is

One molecule, several names

The compound appears in the literature as elamipretide and elamipratide — one molecule, differing only by a transcribed vowel — and older, better known by its code names SS-31 (the Szeto–Schiller series) and MTP-131, with the earlier development name Bendavia. It was designed by Hazel Szeto and Peter Schiller in the early 2000s and developed clinically by Stealth BioTherapeutics. If you cross-read papers, treat all of these as the same entity.

Chemically it is a tetrapeptide — a chain of four residues — D-Arg–Dmt–Lys–Phe-NH₂. Two residues are not ordinary biology: the first is D-arginine, the mirror-image form the body's enzymes are not shaped to cut, and the second is 2′,6′-dimethyltyrosine (Dmt), a modified tyrosine. That gives a molecule this small two rare properties — it resists enzymatic degradation, and its alternating aromatic / positively-charged pattern lets it slip through the plasma membrane and the mitochondrial membranes without a transporter. It is an aromatic-cationic, cell-penetrating peptide that accumulates where almost nothing else concentrates on its own.

02.  The target is a lipid, not a protein

Inside the cell, elamipretide concentrates in mitochondria and binds cardiolipin, an unusual four-tailed phospholipid found almost exclusively on the inner mitochondrial membrane. Cardiolipin is no bystander: it physically organises the electron-transport-chain complexes into higher-order assemblies called supercomplexes² — the arrangement that keeps oxidative phosphorylation, the cell's main route to ATP, running efficiently.

Structural work describes elamipretide altering the electrostatics at the membrane surface and influencing how cardiolipin-dependent proteins assemble. The picture is less “drug blocks enzyme” and more “molecule steadies the lipid landscape the enzymes stand on.” That single mechanism is why it draws interest across a wide span of conditions where mitochondria are stressed.

03.  Why it matters — the open frontier

Mitochondria make most of the body's usable energy, and when they falter the tissues that burn the most energy suffer first — heart, muscle, brain, eye. That places elamipretide at an unusually broad frontier:

• Heart failure & cardiac stress — the failing heart is, in part, an energy-starved heart; a molecule that steadies mitochondrial output is a direct hypothesis to test.
• Primary mitochondrial disease — rare genetic disorders that strike the organelle itself, where few options exist and the unmet need is severe.
• Ageing & the eye — accumulated mitochondrial decline is a thread running through sarcopenia, neurodegeneration and retinal ageing; dry age-related macular degeneration has been an active research setting.

The frontier is genuinely open: a mechanism this general is powerful in principle and hard to pin down in practice, and trial results have been mixed. That tension — a real target, an unsettled clinic — is exactly what makes the space compelling.

04.  Where the science has been explored

Mixed results across indications are the normal shape of an active research field, not a verdict. A broad mechanism is worth probing in many places precisely because no one yet knows where it lands hardest.

Approval, precisely — what the FDA label says

On 19 September 2025 the U.S. Food and Drug Administration approved FORZINITY (elamipretide), NDA 215244, under priority review. The indication, verbatim from the prescribing information:

The qualification the label itself carries, also verbatim:

In plain terms: in the randomised, placebo-controlled crossover part of the TAZPOWER trial (NCT03098797), the label states that “FORZINITY was not superior to placebo on these primary endpoints”, and that the increases in knee extensor muscle strength “were not observed during the randomized trial but were observed during the extension period”. The approval therefore rests on an intermediate endpoint observed in the open-label extension, and continued approval may depend on a confirmatory trial. That trial is 4TAZPower (NCT07531251), a phase 4 randomised, double-blind, placebo-controlled study in Barth syndrome, recruiting since 2 July 2026 with completion estimated for late 2029 — registry dates are estimates, not availability dates.

The approved product is a ready-to-use sterile aqueous solution for subcutaneous injection — 40 mg elamipretide per 0.5 mL dose, preserved with benzyl alcohol, in single-patient-use vials, taken once daily. It is not a dried or lyophilised product.

Honest limits — what the evidence does not establish

• Approval is not proof of clinical benefit. The accelerated approval rests on an intermediate endpoint from an uncontrolled extension; the controlled phase did not show superiority on its primary endpoints. Whether the strength gain translates into clinical benefit is exactly what 4TAZPower is designed to test.
• The open-label extension is uncontrolled. The 168-week TAZPOWER extension (PMID 38602181) reports a cumulative six-minute-walk improvement of 96.1 m at week 168 — with no concurrent control group, and eight of ten participants reaching week 168. Regression, practice effects and natural history are not excluded by that design.
• A missed endpoint is not a mechanism refutation. MMPOWER-3 (NCT03323749) was terminated after its double-blind part missed the primary endpoints — the registry says so in its own words — in an unselected myopathy population. The cardiolipin-binding mechanism is separately evidenced at the biophysical tier (PMIDs 32273339, 35913044), and a genotype-specific post hoc analysis of that trial (PMID 39574155) is hypothesis-generating, not a trial result.
• ReCLAIM-2 missed its primaries — and that is not the whole story. Neither primary endpoint reached statistical significance (PMID 39605874); prespecified structural endpoints showed slower lesion progression at nominal significance, and nominal is not confirmatory. The phase 3 ReNEW trial (NCT06373731), built around the structural endpoint, is under way.
• Binding is not outcome. Membrane binding and surface-electrostatic effects are well evidenced in vitro; the chain from binding to clinical benefit in any given disease is not closed — the 2020 mechanism paper’s own authors propose nonexclusive mechanisms (PMID 32273339).
• The antioxidant label is historical. The field’s framing moved from “peptide antioxidant” (Szeto, 2006) to membrane electrostatics (2020) and structural models (2022); the regulator’s class term is “mitochondrial cardiolipin binder”. Both framings are citable; neither should be presented as settled.
• Storage stability is unmeasured in the public literature. No indexed study of elamipretide solid-state or storage stability was found as of September 2026 — the exact gap Panacea’s preservation research addresses.
• Research material is not the approved drug. The approved product is the defined, labelled dosage form described above; nothing about any third-party research vial’s identity, purity or handling follows from it, and this page makes no claim about any vendor’s material.

05.  A fossil in the membrane — the story

Here is what makes the target quietly astonishing. Roughly a billion and a half years ago, one single-celled organism swallowed a free-living bacterium and, instead of digesting it, kept it. That captive became the mitochondrion — the endosymbiotic event³ that gave complex life its power supply. The bacterium's own membrane came with it, and with it a signature lipid that bacteria make and animal cell-surfaces do not: cardiolipin. To this day cardiolipin sits almost only where that ancient bacterium's membrane became the inner mitochondrial membrane. It is, in effect, a molecular fossil — a chemical fingerprint of a merger older than every animal, plant and fungus on Earth.

Elamipretide reaches past a billion years of evolution to touch that relic lipid directly. A four-residue peptide, engineered in a lab in the 2000s, finding the one surface that still betrays the mitochondrion's bacterial past. That is the mystery worth sitting with: the newest chemistry aimed at the oldest membrane in the cell.

06.  Potential application fields

Where might a cardiolipin-stabilising peptide hit where it hurts most? Reasoned from the mechanism, as inspiration rather than assertion:

• Energy-hungry organ failure — heart and skeletal muscle, where an energy deficit is the core lesion, remain the highest-leverage targets.
• Rare mitochondrial genetics — disorders of the organelle itself, where the unmet need is largest and a mechanism-matched molecule is most direct.
• Ischaemia-reperfusion protection — the burst of oxidative damage when blood returns to a starved tissue (heart attack, stroke, transplant) is a mitochondrial event, and a narrow window where a stabiliser could matter.
• Retinal & neurodegenerative ageing — mitochondria-dense, slowly-declining tissues where small, sustained support could compound.
• Formulation science itself — every one of the above depends on the molecule surviving from synthesiser to patient intact, which is where Panacea's preservation research points.

Frequently asked

Trending in the field

References & further reading

1. Cardiolipin — the signature lipid of the inner mitochondrial membrane. Wikipedia.
2. SS-31 (elamipretide), cardiolipin and mitochondrial supercomplexes / cristae. PubMed search.
3. Endosymbiotic theory — the bacterial origin of the mitochondrion. Wikipedia.
4. Elamipretide (SS-31 / MTP-131) — overview and clinical study record. Wikipedia.
5. Szeto–Schiller aromatic-cationic peptides in mitochondrial protection. PubMed (2014 review).